kairospharma.com - KAPA Operating profit EBITDA
The development of therapeutic platforms at Kairos Pharma Ltd (KAPA) is leading to rising costs in the absence of operating leverage. The company's EBITDA demonstrates profit volatility, where 0.00 captures the current value of the indicator. Stability is provided by California centers and CDMO outsourcing, while success depends on FDA approval and the funding of clinical trials to combat cancer resistance.
Kairos Pharma (KAPA) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Kairos Pharma Ltd|KAPA - Long-Term Debt to Capital|Short-Term Debt to Capital Kairos Pharma Limited|KAPA - Company Aggregate Debts|Debts to Net Assets Kairos Pharma|KAPA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Kairos Pharma|Immediate Liquidity kairospharma.com
- earnings and market ratios statistics:
KAPA - Company Net Income|Company Profit Forecast Kairos Pharma Ltd|KAPA - Price to Earnings Ratio|Future Price to Earnings Multiple Kairos Pharma Limited|KAPA - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Kairos Pharma|KAPA - Operating profit EBITDA|Earnings per share for the trailing year Kairos Pharma|KAPA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth kairospharma.com|KAPA - Earnings per share growth in current year|Expected earnings per share trend next year Kairos Pharma Ltd
- sales revenue and business income indicators:
Summary company analytics:KAPA Kairos Pharma Ltd
Investors in Kairos Pharma Ltd (KAPA) must account for binary outcome risks due to the company's narrow specialization in combating cancer therapy resistance. This metric measures cash flow from core operations before depreciation, reflecting the business's actual ability to act as a cash generator, which, on the EBITDA chart, allows for the identification of abnormal liquidity spikes and prevents overpaying for the asset.
Competitors of Kairos Pharma Ltd (KAPA)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|Operating profit EBITDA erasca.com (ERAS)|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|Aura Bio - Operating profit EBITDA|Operating income before deduction of amortization Candel Therapeutics CADL|Accuray Incorporated (ARAY) - Profit before payment of interest, taxes and amortization|SELLAS Life Sciences Group - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Profit before interest, taxes and amortization Citius Oncology Inc. CTOR|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|Operating income before deduction of amortization Protara Tx|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization WHWK|TCRX - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CSBR|XBIT: Operating profit EBITDA|CEL-SCI - Income before deduction of interest, taxes and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|Operating profit EBITDA radiopharmtheranostics.com|Profit before payment of interest, taxes and amortization Artiva Biotherapeutics, Inc. (ARTV)|ANL (adlainortye.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Pharma VERU|TPST - Operating profit before deduction of amortization|Xilio - Operating profit EBITDA|RENB - Operating profit EBITDA|MURA (muraloncology.com) - Operating profit before deduction of amortization|OnKure Therapeutics - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization CytoMed Therapeutics Ltd|Profit before payment of interest, taxes and amortization CRIS|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (Advanced Biomed)|GNPX: Operating profit before amortization|CLDI - Profit before payment of interest, taxes and amortization|SBFM - Operating profit EBITDA|XBIO: Operating profit EBITDA|salariuspharma.com (SLRX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|AON - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA BGNE|Operating profit EBITDA Checkpoint Therapeutics Inc (CKPT)|Operating profit EBITDA ELEV (Elevation Oncology)|ICAD - Operating profit before deduction of amortization|Ikena - Operating profit EBITDA|NTBL - Operating profit EBITDA|viracta.com (VIRX) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MOR|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
